{"id":4254,"date":"2024-02-29T13:39:28","date_gmt":"2024-02-29T12:39:28","guid":{"rendered":"http:\/\/blog.lallianse.com\/?p=4254"},"modified":"2024-10-16T11:40:51","modified_gmt":"2024-10-16T09:40:51","slug":"do-you-speak-lallianse-25-carole-neves-biotechstudio-2","status":"publish","type":"post","link":"https:\/\/blog.lallianse.com\/index.php\/en\/do-you-speak-lallianse-25-carole-neves-biotechstudio-2\/","title":{"rendered":"Do you speak LallianSe ? #25 Carole Nev\u00e8s, BiotechStudio"},"content":{"rendered":"\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"Do you speak LallianSe ? #25 Carole Nev\u00e8s, BiotechStudio\" width=\"840\" height=\"473\" src=\"https:\/\/www.youtube.com\/embed\/n-bQz5InIQ8?list=PLCmrxoC_xfLk8NoLvPtiG9Bv7vV8jjPVM\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">First integrated into the LallianSe <strong>#community<\/strong> through our <strong>#events<\/strong>, <a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/company\/11090258\/admin\/feed\/posts\/#\" target=\"_blank\">Carole Neves<\/a> joined our <strong>#community <\/strong>of <strong>#Experts<\/strong> in residence as Sparring and Operating partner, particularly with <a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/company\/11090258\/admin\/feed\/posts\/#\" target=\"_blank\">EVerZom<\/a> and international clients.<\/p>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">Our common ambition to support the creation and development of start-ups, combined with <a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/company\/11090258\/admin\/feed\/posts\/#\" target=\"_blank\">Carole<\/a>&lsquo;s keen <strong>#expertise<\/strong> in rare diseases, gene therapies and other innovative products, allows us to offer a 360\u00b0 vision of the challenges of business development and health products<\/p>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">Ultimately, it is a <strong>#synergy<\/strong> that supports the startup\u2019s value creation and actively contributes to its success.<\/p>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">Meet <a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/company\/11090258\/admin\/feed\/posts\/#\" target=\"_blank\">Carole Neves<\/a> in our <strong>#\ud835\udc03\ud835\udc28\ud835\udc18\ud835\udc28\ud835\udc2e\ud835\udc12\ud835\udc29\ud835\udc1e\ud835\udc1a\ud835\udc24\ud835\udc0b\ud835\udc1a\ud835\udc25\ud835\udc25\ud835\udc22\ud835\udc1a\ud835\udc27\ud835\udc12\ud835\udc1e<\/strong>?<\/p>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">\u00a0<strong>#health #DYSL<\/strong> <strong>#team<\/strong> <strong>#Expert<\/strong> <strong>#XIR<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>First integrated into the LallianSe #community through our #events, Carole Neves joined our #community of #Experts in residence as Sparring and Operating partner, particularly with EVerZom and international clients. Our common ambition to support the creation and development of start-ups, combined with Carole&lsquo;s keen #expertise in rare diseases, gene therapies and other innovative products, allows &hellip; <a href=\"https:\/\/blog.lallianse.com\/index.php\/en\/do-you-speak-lallianse-25-carole-neves-biotechstudio-2\/\" class=\"more-link\">Continuer la lecture<span class=\"screen-reader-text\"> de &laquo;&nbsp;Do you speak LallianSe ? #25 Carole Nev\u00e8s, BiotechStudio&nbsp;&raquo;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"footnotes":"","_jetpack_memberships_contains_paid_content":false},"categories":[151,240],"tags":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts\/4254"}],"collection":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/comments?post=4254"}],"version-history":[{"count":1,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts\/4254\/revisions"}],"predecessor-version":[{"id":4255,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts\/4254\/revisions\/4255"}],"wp:attachment":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/media?parent=4254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/categories?post=4254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/tags?post=4254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}